Released by the Pandemic Response Accountability Committee, the report looks at data on test volume, turnaround, cost, and usage at six federal agencies.
The company said it expects core molecular testing revenue between $115 million and $125 million and SARS-CoV-2 revenue between $15 million and $20 million.
The funding will be used to validate the Simplexa COVID-19 Direct kit and Simplexa COVID-19 & Flu A/B Direct kit and to submit them to the FDA for 510(k) clearance.
The lateral flow test can be used at the point of care and provides results within 15 minutes without the need for additional equipment, the company said.
The firm is projecting COVID-19 testing revenues of $865 million in the recently completed quarter, including $685 million in Veritor immunoassay sales.
The assay can be used to determine the immune status of COVID-19 patients and individuals who have been vaccinated against the virus, the company said.
The government said that rapid, regular testing of asymptomatic patients will be expanded to cover all 317 local authorities in the country starting next week.
The disposable rapid antigen test uses lateral flow technology to detect SARS-CoV-2 in 15 minutes, and Everlywell will distribute it to workplaces, schools, and other organizations.
